Inektran solution for injection 100mg / ml, 2ml No. 10

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of the peripheral joints;

• intervertebral osteochondrosis and osteoarthritis.

To accelerate the formation of callus in fractures.

In / m, 1 ml every other day. With good tolerance, the dose is increased to 2 ml, starting with the fourth injection. The course of treatment is 25-35 injections. If necessary, a second course of treatment is possible after 6 months. The duration of repeated courses of treatment is determined by the doctor.

For the formation of callus, the course of treatment is 3-4 weeks (10-14 injections every other day).

Solution for intramuscular injection is transparent, colorless or slightly yellowish.

1 ml chondroitin sodium sulfate 100 mg

Excipients: sodium disulfite - 2 mg, methyl parahydroxybenzoate - 0.5 mg, 1M sodium hydroxide solution - up to pH 6.0-7.5, water d / i - up to 1 ml.

• Hypersensitivity to chondroitin sulfate;

• bleeding, bleeding tendency;

• thrombophlebitis;

• pregnancy;

• the period of breastfeeding (during treatment, breastfeeding should be discontinued);

• children's age (data on efficacy and safety are not available).

pharmachologic effect

Chondroitin sulfate is the main component of proteoglycans, which together with collagen fibers make up the cartilage matrix.

It has a chondrostimulating, regenerating, anti-inflammatory and analgesic effect. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue. Has chondroprotective properties; enhances metabolic processes in hyaline and fibrous cartilage and subchondral bone; inhibits the activity of enzymes that cause degradation (destruction) of the articular cartilage; stimulates the production of proteoglycans by chondrocytes; influences phosphorus-calcium metabolism in cartilaginous tissue, stimulates its regeneration, participates in the construction of the basic substance of bone and cartilage tissue. It has anti-inflammatory and analgesic properties, helps to reduce the release of inflammatory mediators and pain factors into the synovial fluid through synoviocytes and macrophages of the synovial membrane,inhibits the secretion of leukotrienes and prostaglandins. The drug prevents the degeneration of connective tissue and reduces calcium loss, accelerates the processes of bone tissue regeneration.

Chondroitin sulfate slows down the progression of osteoarthritis and osteochondrosis. Promotes the restoration of the joint capsule and cartilaginous surfaces of the joints, prevents the collapse of connective tissue, normalizes the production of joint fluid.

The clinical effect is manifested by an improvement in the mobility of the joints, a decrease in the intensity of pain, while the therapeutic effect lasts a long time after the end of the course of therapy. In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed within 2-3 weeks from the start of the course.

Structurally similar to heparin, it can potentially prevent the formation of fibrin thrombi in the synovial and subchondral microcircular bed.

Pharmacokinetics

Absorption and distribution

Chondroitin sodium sulfate is easily absorbed by intramuscular injection. 30 minutes after i / m administration, it is found in the blood in significant concentrations; after 15 minutes - in the synovial fluid. Cmax in blood plasma is reached 1 hour after administration, then the concentration of the drug gradually decreases within 2 days.

Accumulates mainly in cartilage tissue (Cmax in articular cartilage is reached after 48 hours); the synovium is not an obstacle to the penetration of the drug into the joint cavity.

Withdrawal

It is excreted from the body mainly by the kidneys within 24 hours.

Side effect

When using the drug in persons with hypersensitivity to the drug, the following violations are possible.

From the immune system: allergic reactions, angioedema.

On the part of the skin and subcutaneous fat: skin rash, itching, erythema, urticaria, dermatitis.

From the digestive system: dyspeptic symptoms.

Local reactions: redness, itching, hemorrhages are possible at the injection site.

Application during pregnancy and lactation

The use of InjectranЃ during pregnancy is contraindicated. If the drug is used during breastfeeding, breastfeeding should be discontinued.

special instructions

It is recommended to increase doses under the supervision of a physician for patients with overweight, gastric ulcer or duodenal ulcer, while taking diuretics, as well as at the beginning of treatment, if necessary to accelerate the clinical response.

In the event of allergic reactions or hemorrhages, treatment should be discontinued.

Use in pediatrics

There are currently no data on the efficacy and safety of chondroitin sulfate in children.

Influence on the ability to drive vehicles and mechanisms

In the recommended dose range, the effect on concentration and psychomotor speed has not been established. When taken in high doses, it is recommended to be careful when driving vehicles, working with mechanisms and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Overdose

Currently, no cases of InjectranЃ drug overdose have been reported.

Symptoms: it can be assumed that if the daily dose is exceeded, the side effects of the drug may increase.

Treatment: carrying out symptomatic therapy.

Drug interactions

It is possible to enhance the action of indirect anticoagulants, antiplatelet agents and fibrinolytics, which requires more frequent monitoring of blood coagulation indicators when used together.

Shows synergism of action when used simultaneously with glucosamine and other chondroprotectors.